Cagliostro et al. evaluated the safety of SGLT2-i in the LVAD population with T2DM and found non-SGLT2-i specific adverse events, such as acute kidney injury, urinary tract infections, and limb amputations [7]. Here, SLC5A2 is linked to type 2 diabetes mellitus.